Patents Assigned to Aventis Pharmaceuticals Inc.
-
Publication number: 20110263831Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.Type: ApplicationFiled: June 10, 2011Publication date: October 27, 2011Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: June KAPLOW, Thomas HAWS, Marie ROSIER, Patrice DENEFLE
-
Publication number: 20110251240Abstract: A dosing regimen comprising a therapeutically effective amount of flavopiridol or a pharmaceutically acceptable salt thereof optionally in combination with a pharmaceutically acceptable carrier suitable for bolus infusion and subsequently for infusion is disclosed and claimed. Also disclosed and claimed is a method of treating a variety of cancers in a patient comprising administering to said patient the dosing regimen of the invention.Type: ApplicationFiled: December 16, 2010Publication date: October 13, 2011Applicants: OHIO STATE UNIVERSITY RESEARCH FOUNDATION, AVENTIS PHARMACEUTICALS INC.Inventors: Jose-Ramon SUAREZ, John BYRD, Michael GREVER, James DALTON, Thomas LIN
-
Publication number: 20110245471Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacutre of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.Type: ApplicationFiled: June 10, 2011Publication date: October 6, 2011Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: June KAPLOW, Thomas HAWS, Marie ROSIER, Patrice DENEFLE
-
Publication number: 20110230455Abstract: An aqueous pharmaceutical composition which is capable of being sprayed into the nasal cavity of an individual and which comprises: (A) a pharmaceutically effective amount of solid particles of medicament which is effective in treating a bodily condition by virtue of its being present on the mucosal surfaces of the nasal cavity; and (B) a suspending agent in an amount effective to maintain said particles dispersed uniformly in the composition and to impart to the composition the following thixotropic properties: (i) the viscosity of the position in unsheared form is relatively high, with the composition being in gel-like form; (ii) as the composition is subjected to shear (shaken) in preparation for spraying, the viscosity of the composition becomes relatively low and such that the composition in the form of a mist flows readily into the nasal passages for deposit on the mucosal surfaces of the nasal cavity; and (D) in deposited form on the mucosal surfaces, the viscosity of the composition is relatively highType: ApplicationFiled: May 31, 2011Publication date: September 22, 2011Applicant: AVENTIS PHARMACEUTICALS INC.Inventor: Soo-Il KIM
-
Patent number: 8008491Abstract: The present invention relates to a series of substituted aza-indole derivatives of the formula I: wherein R, R1, R2, R3, R4, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.Type: GrantFiled: June 17, 2008Date of Patent: August 30, 2011Assignee: Aventis Pharmaceuticals, Inc.Inventors: John Ziqi Jiang, Jack Roger Koehl, Shujaath Mehdi, Neil Moorcroft, Kwon Yon Musick, Philip Marvin Weintraub, Paul Robert Eastwood
-
Patent number: 8008340Abstract: A method for inhibiting casein kinase I? activity, comprising administering to said patient a therapeutically effective amount of a compound of formula I. its stereoisomer, enantiomer, racemate, tautomer or pharmaceutically acceptable salt thereof.Type: GrantFiled: February 15, 2007Date of Patent: August 30, 2011Assignee: Aventis Pharmaceuticals Inc.Inventor: William Arthur Metz, Jr.
-
Patent number: 7989584Abstract: The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.Type: GrantFiled: December 9, 2009Date of Patent: August 2, 2011Assignee: Aventis Pharmaceuticals Inc.Inventors: Kun Guo, Kenneth L. Clark, Yuri D. Ivashchenko, Marco Pagnoni
-
Patent number: 7977045Abstract: An aqueous pharmaceutical composition which is capable of being sprayed into the nasal cavity of an individual and which comprises: (A) a pharmaceutically effective amount of solid particles of medicament which is effective in treating a bodily condition by virtue of its being present on the mucosal surfaces of the nasal cavity; and (B) a suspending agent in an amount effective to maintain said particles dispersed uniformly in the composition and to impart to the composition the following thixotropic properties: (i) the viscosity of the position in unsheared form is relatively high, with the composition being in gel-like form; (ii) as the composition is subjected to shear (shaken) in preparation for spraying, the viscosity of the composition becomes relatively low and such that the composition in the form of a mist flows readily into the nasal passages for deposit on the mucosal surfaces of the nasal cavity; and (D) in deposited form on the mucosal surfaces, the viscosity of the composition is relatively highType: GrantFiled: March 22, 2010Date of Patent: July 12, 2011Assignee: Aventis Pharmaceuticals Inc.Inventor: Soo-Il Kim
-
Patent number: 7977310Abstract: This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient.Type: GrantFiled: June 17, 2008Date of Patent: July 12, 2011Assignee: Aventis Pharmaceuticals Inc.Inventors: Ralf Rosskamp, Hertzel Gerstein
-
Patent number: 7972844Abstract: The present invention is directed to nuclear factor ?B (NF?B)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NF?B. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NF?B induction in a patient, methods and compositions for lowering NF?B induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treatment and/or prevention of an NF?B-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided.Type: GrantFiled: February 15, 2006Date of Patent: July 5, 2011Assignee: Aventis Pharmaceuticals Inc.Inventors: June Kaplow, Thomas Haws, Marie Rosier, Patrice Denefle
-
Patent number: 7947684Abstract: This invention relates to compounds of formula which inhibit Factor Xa or tryptase, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa or tryptase.Type: GrantFiled: July 8, 2003Date of Patent: May 24, 2011Assignee: Aventis Pharmaceuticals Inc.Inventors: Heinz Pauls, Yong Gong, Julian Levell, Peter Astles, Paul R. Eastwood
-
Patent number: 7943616Abstract: The invention is directed to physiologically active compounds of general formula (I):— and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.Type: GrantFiled: November 23, 2004Date of Patent: May 17, 2011Assignee: Aventis Pharmaceuticals Inc.Inventors: Paul J. Cox, Tahir N. Majid, Justine Yeun Quai Lai, Andrew D. Morley, Shelley Amendola, Stephanie D. Deprets, Christopher Edlin, Charles J. Gardner, Dorothea Kominos, Brian L. Pedgrift, Frank Halley, Timothy A. Gillespy, Michael Edwards, Francois F. Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel N. A. Bezard, Chantal Carrez
-
Patent number: 7928231Abstract: Thienopyrazoles of formula I, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK).Type: GrantFiled: March 26, 2009Date of Patent: April 19, 2011Assignee: Aventis Pharmaceuticals Inc.Inventors: John Gerard Jurcak, Matthieu Barrague, Timothy Alan Gillespy, Michael Louis Edwards, Kwon Yon Musick, Philip Marvin Weintraub, Yan Du, Ramalinga M. Dharanipragada, Ashfaq Ahmad Parkar
-
Patent number: 7923466Abstract: Methods for the treatment of a patient suffering from a disease or disorder ameliorated by inhibition of casein kinase I? activity comprising the administration of a compounds of formula (I) and formula (II) as inhibitors of human casein kinase I?, and methods of using the compounds of formula (I) and formula (II) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. The R-group substituents are defined herein and pharmaceutical compositions comprising compounds of formula (I) or formula (II) useful in the claimed methods of treatment are also disclosed.Type: GrantFiled: November 12, 2008Date of Patent: April 12, 2011Assignee: Aventis Pharmaceuticals Inc.Inventors: William Arthur Metz, Jr., Fa-Xiang Ding
-
Patent number: 7919508Abstract: The present invention provides compounds of formula I: a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, X and n are defined as defined herein. Additionally, a method for treating dopamine-related neurological disorders selected form the group consisting of neurological, psychological, cardiovascular, cognitive or attention disorders, substance abuse and addictive behavior, or a combination thereof, comprising administering to a patient in need of such treatment a therapeutically effective amount of compounds of formula I.Type: GrantFiled: October 24, 2006Date of Patent: April 5, 2011Assignee: Aventis Pharmaceuticals Inc.Inventors: Gregory Shutske, Keith J. Harris, Kenneth J. Bordeau, Michael R. Angelastro, Stanly John, Joseph T. Klein, Jinqi Lu, Catherine Bomont
-
Patent number: 7884200Abstract: Provided herein are retroviral vectors for delivering interfering RNA into cells.Type: GrantFiled: October 7, 2009Date of Patent: February 8, 2011Assignee: Aventis Pharmaceuticals Inc.Inventors: Dorre Grueneberg, Gerard Bain, Nayantara Kothari
-
Patent number: 7777042Abstract: A composition for binding FKBP proteins is disclosed, along with a method of treating conditions associated with neuronal degeneration, wherein said composition comprises a compound of formula I, wherein, R, R1, R2, R3 and X are as defined herein.Type: GrantFiled: December 6, 2006Date of Patent: August 17, 2010Assignee: Aventis Pharmaceuticals Inc.Inventors: Raymond W. Kosley, Jr., Bruce Baron, Patrick Jimonet, John G. Jurcak, Stephen J. Shimshock, Xu-Yang Zhao, Rosy Sher, Paul J. Mueller, Jennifer Beall, Matthieu Barrague, Joseph W. Guiles
-
Patent number: 7772252Abstract: The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.Type: GrantFiled: April 17, 2009Date of Patent: August 10, 2010Assignee: Aventis Pharmaceuticals Inc.Inventors: James Hendrix, Horst Hemmerle, Matthias Urmann, Gregory M Shutske, Joseph T Strupczewski, Kenneth J Bordeau, John G Jurcak, Thaddeus Nieduzak, Sharon A. Jackson, Paul Angell, James P Carey, George Lee, David Fink, Jean-Francois Sabuco, Yulin Chiang, Nicola Collar
-
Patent number: 7754678Abstract: The present invention is directed to membrane penetrating peptides useful as in vivo, ex vivo and in vitro intracellular delivery devices for compound of interest. More particularly, the invention involves identification of membrane penetrating peptides which may be used as protein carriers for delivery of a compound of interest to cells, to methods of delivering a compound of interest attached to membrane penetrating peptides to cells.Type: GrantFiled: October 17, 2005Date of Patent: July 13, 2010Assignee: Aventis Pharmaceuticals Inc.Inventors: Yong Guo, Clarence C Morse, Zhengbin Yao, George Keesler
-
Patent number: H2246Abstract: A method for predicting the effectiveness of medication-based therapy in lowering average blood glucose levels in a diabetic patient is provided. This method may further comprise selectively recommending a medication-based therapy on the basis of the arithmetic average of the relative minima. A method for determining susceptibility to symptomatic hypoglycemia in a patient is provided. This method may further comprise selectively recommending a medication-based therapy on the basis of the arithmetic average of the relative minima. Provided also is a device for continuously monitoring blood glucose levels in a patient. The methods and device involve applying a Fourier approximation to blood glucose level data.Type: GrantFiled: February 28, 2007Date of Patent: August 3, 2010Assignee: Aventis Pharmaceuticals Inc.Inventors: Michael Franklin Miller, Poul Strange